Cargando…

Looking beyond occlusion: A novel perspective for amblyopia treatment

PURPOSE: The aim of this study was to evaluate the efficacy of Orthoptek (Magnocellular Stimulator OMS; Carditek Pvt. Ltd., Bangalore) as a treatment modality for amblyopia and strabismus. METHODS: Thirty-five patients with amblyopia of any type, reduced vision in one or both eyes with no binocular...

Descripción completa

Detalles Bibliográficos
Autores principales: Santhan Gopal, KS, Jayadev, Chaitra, Thomas, Sherina, Gopal, Sugandhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774144/
https://www.ncbi.nlm.nih.gov/pubmed/33120641
http://dx.doi.org/10.4103/ijo.IJO_741_20
_version_ 1783630201525108736
author Santhan Gopal, KS
Jayadev, Chaitra
Thomas, Sherina
Gopal, Sugandhi
author_facet Santhan Gopal, KS
Jayadev, Chaitra
Thomas, Sherina
Gopal, Sugandhi
author_sort Santhan Gopal, KS
collection PubMed
description PURPOSE: The aim of this study was to evaluate the efficacy of Orthoptek (Magnocellular Stimulator OMS; Carditek Pvt. Ltd., Bangalore) as a treatment modality for amblyopia and strabismus. METHODS: Thirty-five patients with amblyopia of any type, reduced vision in one or both eyes with no binocular vision and or poor stereopsis were included in the study. All patients underwent a minimum of 10 sessions of therapy with each session lasting for a cumulative period of 60 min. At the end of the 10(th) session, patients were evaluated for improvement in visual acuity, stereopsis, Binocular single vision and amount of strabismus, if any. RESULTS: The mean logMAR corrected distance visual acuity improved from 0.31 ± 0.34 and 0.32 ± 0.44 to 0.08 ± 0.12 and 0.07 ± 0.12 posttreatment in the right eye and left eye, respectively. Following therapy, 34 (97%) patients showed improvement in stereopsis, orthophoria was noticed in 28 (80%), and binocular single vision was noted in 33 (94%). All patients were followed up for 1 year with maintenance therapy and none showed any regression. CONCLUSION: We believe that top–down impulses and the role of the attention area in the parietal cortex have not been studied well enough in the treatment of amblyopia. Our device addresses these issues and corrects the visual deficits in amblyopia. However, the study needs validation of this pilot study from independent centers. The same will be done at some stage
format Online
Article
Text
id pubmed-7774144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77741442021-01-07 Looking beyond occlusion: A novel perspective for amblyopia treatment Santhan Gopal, KS Jayadev, Chaitra Thomas, Sherina Gopal, Sugandhi Indian J Ophthalmol Original Article PURPOSE: The aim of this study was to evaluate the efficacy of Orthoptek (Magnocellular Stimulator OMS; Carditek Pvt. Ltd., Bangalore) as a treatment modality for amblyopia and strabismus. METHODS: Thirty-five patients with amblyopia of any type, reduced vision in one or both eyes with no binocular vision and or poor stereopsis were included in the study. All patients underwent a minimum of 10 sessions of therapy with each session lasting for a cumulative period of 60 min. At the end of the 10(th) session, patients were evaluated for improvement in visual acuity, stereopsis, Binocular single vision and amount of strabismus, if any. RESULTS: The mean logMAR corrected distance visual acuity improved from 0.31 ± 0.34 and 0.32 ± 0.44 to 0.08 ± 0.12 and 0.07 ± 0.12 posttreatment in the right eye and left eye, respectively. Following therapy, 34 (97%) patients showed improvement in stereopsis, orthophoria was noticed in 28 (80%), and binocular single vision was noted in 33 (94%). All patients were followed up for 1 year with maintenance therapy and none showed any regression. CONCLUSION: We believe that top–down impulses and the role of the attention area in the parietal cortex have not been studied well enough in the treatment of amblyopia. Our device addresses these issues and corrects the visual deficits in amblyopia. However, the study needs validation of this pilot study from independent centers. The same will be done at some stage Wolters Kluwer - Medknow 2020-11 2020-10-26 /pmc/articles/PMC7774144/ /pubmed/33120641 http://dx.doi.org/10.4103/ijo.IJO_741_20 Text en Copyright: © 2020 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Santhan Gopal, KS
Jayadev, Chaitra
Thomas, Sherina
Gopal, Sugandhi
Looking beyond occlusion: A novel perspective for amblyopia treatment
title Looking beyond occlusion: A novel perspective for amblyopia treatment
title_full Looking beyond occlusion: A novel perspective for amblyopia treatment
title_fullStr Looking beyond occlusion: A novel perspective for amblyopia treatment
title_full_unstemmed Looking beyond occlusion: A novel perspective for amblyopia treatment
title_short Looking beyond occlusion: A novel perspective for amblyopia treatment
title_sort looking beyond occlusion: a novel perspective for amblyopia treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774144/
https://www.ncbi.nlm.nih.gov/pubmed/33120641
http://dx.doi.org/10.4103/ijo.IJO_741_20
work_keys_str_mv AT santhangopalks lookingbeyondocclusionanovelperspectiveforamblyopiatreatment
AT jayadevchaitra lookingbeyondocclusionanovelperspectiveforamblyopiatreatment
AT thomassherina lookingbeyondocclusionanovelperspectiveforamblyopiatreatment
AT gopalsugandhi lookingbeyondocclusionanovelperspectiveforamblyopiatreatment